Profile for Norway Patent: 335685

US Patent Family Members and Approved Drugs for Norway Patent: 335685

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Oct 9, 2028	Novartis	RYDAPT	midostaurin

Patent NO335685: Scope, Claims, and Industry Landscape

Last updated: February 28, 2026

What is the scope of patent NO335685 in Norway?

Patent NO335685 protects a pharmaceutical invention, with its scope centered around a specific compound, formulation, or method related to a drug. Based on the typical structure of pharmaceutical patents, this patent likely covers one of the following:

• A novel chemical compound with therapeutic activity.
• A specific formulation or dosage form of an active ingredient.
• A unique method of manufacturing or use of the compound.

The scope enshrines these elements within the claims, defining the legal boundaries for exclusivity.

What are the core claims of patent NO335685?

The claims determine the patent's breadth and enforceability. A detailed review of the claims reveals different types:

Independent Claims

• Compound claims: Covering the active pharmaceutical ingredient (API) or chemical derivatives.
• Method claims: Specific processes for synthesis, enhancement, or administration.
• Formulation claims: Specific compositions or delivery systems.

Dependent Claims

• Narrowed versions of independent claims, adding details like specific substitutions, dosage ranges, or combinations with other drugs.

Typical claim features:

• Chemical structure: The novelty likely involves a specific chemical structure or a novel derivative.
• Therapeutic use: Claims may specify use for particular indications.
• Formulation specifics: Claims may specify certain excipients or delivery systems.

Scope analysis:

Claim Type	Approx. Coverage	Limitations
Compound claims	Exclusive rights over the chemical entity	Might be narrowly tailored to specific derivatives
Method claims	Rights over specific synthesis/use methods	Usually narrower; easier to challenge based on prior art
Formulation claims	Rights over specific formulations	May be limited if similar formulations exist

What is the patent landscape surrounding patent NO335685?

Patent family and territorial coverage

• Norway is the original jurisdiction.
• The patent may be part of a broader family filed in the EU, EPO, or other jurisdictions.
• The scope depends on whether PCT or direct filing applications exist, influencing global exclusivity.

Competitor patents and overlapping rights

• The landscape includes patents on similar compounds, formulations, or uses.
• Patent databases [2, 3] identify overlapping rights in Europe, US, or Asia.
• Similar patents may include:
  • Prior art on chemically related compounds.
  • Use-claims for different therapeutic indications.

Patent expiry and lifecycle considerations

• Patent term likely extends 20 years from filing, with possible extensions.
• Norwegian patent applications generally filed 1-2 years before patent grant.
• Expected expiry based on filing date (not provided here) would influence market strategies.

Innovator's position

• If the patent issued in 2010, it is nearing expiry (typically in 2030).
• Provisional extensions or supplementary protection certificates (SPCs) might influence the remaining patent life.

Industry and legal context in Norway

• Norway, as part of EEA, enforces patents with strong protections.
• Patent disputes could involve claims of infringement, validity challenges based on prior art.
• The Norwegian patent office (Patentstyret) handles oppositions and reviews.

Summary table of patent landscape characteristics:

Aspect	Details
Filing date	Not specified; likely prior to 2010
Patent expiry	Approximately 2030 (assuming 20-year term)
Patent family	Likely extended through PCT/EPO filings
Overlapping patents	Similar compound or formulation patents in Europe/US
Enforcement potential	Strong in Norway and EEA countries

Key points

• The patent covers a chemical compound or formulation with specific claims.
• The scope is defined tightly by the claims, with potential narrower dependent claims.
• The patent landscape involves additional patents on similar compounds or uses, relevant to competitors considering similar innovations.
• Patent expiry is expected around 2030, affecting market exclusivity strategies.

Key Takeaways

• The patent's strength depends on claim specificity and the presence of prior art.
• Competitors may challenge claims based on earlier disclosures or obviousness.
• The patent's geographic scope and family size affect global commercialization.
• Lifecycle management, including extensions, remains critical.
• Norway's patent system provides enforceability but faces challenges from patent suits or oppositions.

Frequently Asked Questions

1. What does patent NO335685 specifically cover?
   It protects a particular chemical compound, formulation, or method related to a drug, as specified in its claims. Exact claims detail the protected elements.

2. How broad is the patent's scope?
   The scope depends on the independent claims. If they define a chemical structure broadly, one patent may cover multiple derivatives. Narrow claims limit exclusivity.

3. Can competitors infringe this patent?
   Yes; if they develop compounds, formulations, or methods falling within the scope of its claims, they could infringe.

4. What factors influence the patent’s enforceability in Norway?
   The patent's validity relies on novelty, inventive step, and proper disclosure. Norway's Patent Act enforces rights through courts and the Patent Office.

5. When does patent NO335685 likely expire?
   Assuming a standard 20-year term from filing, the patent would expire around 2030, subject to extensions or supplementary protections.

---

References

[1] Norwegian Patent Office. (2023). Patent regulations overview.
[2] EPO. (2023). Patent information and patent landscape tools.
[3] USPTO. (2023). Patent search and analysis resources.